The FDA has granted breakthrough therapy designation to Biogen’s litifilimab for CLE, a chronic autoimmune skin condition.

Sensorion has announced a $71.9m reserved offering through the issuance of 214,285,714 new ordinary shares at €0.28 per share to advance the development of its gene therapy pipeline.

This year, sales of Eliquis (apixaban) are projected to decline by 15.2% due to the loss of its European market exclusivity ...

Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss. In a move that ...

Real-world evidence (RWE) empowers payers and providers to make more informed, cost-effective treatment. Read more here: ...

Ocado is adapting its advanced grocery fulfilment technology for pharmaceutical warehousing. Here's what it wants to achieve.

Insilico Medicine has entered a strategic partnership with Qilu Pharmaceutical to develop treatments for cardiometabolic diseases.

The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.

Other countries in Europe to lose eliminated status include Armenia, Austria, Azerbaijan, Spain, and Uzbekistan. Sustained ...

The lack of initial public offerings (IPOs) also reflects a year of restricted growth. As per the BIA, no UK biotechs went ...

The two companies reportedly could not agree on a price, leaving pharma’s first potential megadeal of 2026 on ice.